Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2421-2423.e2. doi: 10.1016/j.cgh.2022.07.035. Epub 2022 Aug 6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bevacizumab / adverse effects
  • Carcinoma, Hepatocellular* / drug therapy
  • Esophageal and Gastric Varices*
  • Gastrointestinal Hemorrhage / chemically induced
  • Humans
  • Liver Neoplasms* / drug therapy
  • Varicose Veins*

Substances

  • Bevacizumab
  • atezolizumab